Demographics and Baseline Characteristics of Children With Atopic Dermatitis Enrolled in a Randomized Phase 3 Study (TRuE-AD3)

被引：0
|
作者：
Siri, Dareen [1 ]
Lee, Lara Wine [2 ]
Gold, Linda Stein [3 ]
Armstrong, April [4 ]
Brar, Kanwaljit [5 ]
Holland, Kristen [6 ]
Shepard, Julie [7 ]
Devani, Alim [8 ]
Sturm, Daniel [9 ]
Angel, Brett [9 ]
Li, Qian [9 ]
Eichenfield, Lawrence [10 ]
机构：
[1] Midwest Allergy Sinus Asthma, Bloomington, IL USA
[2] Med Univ South Carolina, Charleston, SC USA
[3] Henry Ford Hlth Syst, Detroit, MI USA
[4] Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA USA
[5] NYU Langone Hlth Ctr, Hassenfeld Childrens Hosp, New York, NY USA
[6] Med Coll Wisconsin, Milwaukee, WI USA
[7] Ohio Pediat Res Assoc, Dayton, OH USA
[8] Dermatol Res Inst, Calgary, AB, Canada
[9] Incyte Corp, Wilmington, DE USA
[10] Univ Calif San Diego, San Diego, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
021
引用
收藏
页码：AB8 / AB8
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF RUXOLITINIB CREAM IN CHILDREN WITH ATOPIC COMORBIDITIES: TRUE-AD3 SUBGROUP ANALYSIS
    Soong, W.
    Lee, L. Wine
    Simpson, E.
    Zaenglein, A.
    Angel, B.
    Sturm, D.
    Ren, H.
    Brar, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S97 - S98
  • [2] Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study
    Eichenfield, Lawrence F.
    Armstrong, April W.
    Gold, Linda F. Stein
    Zaenglein, Andrea L.
    Lee, Lara Wine
    Brar, Kanwaljit K.
    Joyce, Joel C.
    Holland, Kristen E.
    Angel, Brett
    Sturm, Daniel
    Li, Qian
    Simpson, Eric L.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [3] DEMOGRAPHICS AND BASELINE CHARACTERISTICS OF THE NALMEFENE PHASE 3 PROGRAMME STUDY POPULATION
    Gual, A.
    Sorensen, P.
    ALCOHOL AND ALCOHOLISM, 2013, 48 : 46 - 46
  • [4] Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: Pooled subgroup analysis from two randomized phase 3 studies
    Papp, Kim
    Szepietowski, Jacek C.
    Kircik, Leon
    Toth, Darryl
    Eichenfield, Lawrence F.
    Forman, Seth B.
    Armstrong, April W.
    Kuligowski, Michael E.
    Venturanza, May E.
    Sun, Kang
    Simpson, Eric L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB149 - AB149
  • [5] Dupilumab for atopic dermatitis in children aged ≥6 to <12 years in phase 3 LIBERTY AD PEDS trial: Analysis by baseline weight
    Paller, A. S.
    Siegfried, E. C.
    Beck, L. A.
    O'Malley, J. T.
    Shumel, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : B9 - B9
  • [6] Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics
    Thyssen, J. P.
    Thaci, D.
    Bieber, T.
    Gooderham, M.
    de Bruin-Weller, M.
    Soong, W.
    Kabashima, K.
    Barbarot, S.
    Luna, P. C.
    Xu, J.
    Hu, X.
    Liu, Y.
    Raymundo, E. M.
    Calimlim, B. M.
    Nduaka, C.
    Gamelli, A.
    Simpson, E. L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, : 1871 - 1880
  • [7] Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies
    Papp, Kim
    Szepietowski, Jacek C.
    Kircik, Leon
    Toth, Darryl
    Eichenfield, Lawrence F.
    Forman, Seth B.
    Thaci, Diamant
    Kuligowski, Michael E.
    Venturanza, May E.
    Sun, Kang
    Simpson, Eric L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB160 - AB160
  • [8] Apitegromab in spinal muscular atrophy: baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study
    Crawford, T.
    Servais, L.
    Krueger, J.
    Koelbel, H.
    Garcia, M. Gomez
    Cances, C.
    Kuntz, N.
    Finkel, R.
    Yao, B.
    Zhao, G.
    Marantz, J.
    Darras, B.
    Mercuri, E.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [9] Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis
    Alkhouri, Naim
    Wong, Vincent Wai-Sun
    Jablkowski, Maciej
    de Guevara, Alma Laura Ladron
    Sheikh, Muhammad
    Hodge, Alex
    Elkhashab, Magdy
    Strasser, Simone
    Park, Grace S.
    Landgren, Henrik
    Tan, Bill
    Massetto, Benedetta
    Pecoraro, Maria Lucia
    Seyedkazemi, Star
    Martins, Eduardo Bruno
    Fischer, Laurent
    Abdelmalek, Manal
    Tetri, Brent
    Anstee, Quentin
    JOURNAL OF HEPATOLOGY, 2020, 73 : S508 - S508
  • [10] Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD)
    Park, Chun Wook
    Kim, Beom Joon
    Lee, Yang Won
    Won, Chonghyun
    Park, Chang Ook
    Chung, Bo Young
    Lee, Dong Hun
    Jung, Kyoungmi
    Nam, Hyun-Jin
    Choi, Gyeyoung
    Park, Young-Ho
    Kim, Kyu Han
    Park, Miyoung
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (04) : 1340 - +
12345